These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER? Banach M; Penson PE Cardiovasc Res; 2019 Mar; 115(3):e26-e31. PubMed ID: 30605511 [No Abstract] [Full Text] [Related]
6. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy? Cervelli N; Tocci G; Ferri C High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812 [No Abstract] [Full Text] [Related]
7. The 2018 AHA/ACC/Multi-Society Cholesterol guidelines: Looking at past, present and future. Stone NJ; Grundy SM Prog Cardiovasc Dis; 2019; 62(5):375-383. PubMed ID: 31733217 [TBL] [Abstract][Full Text] [Related]
8. PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review. Handelsman Y; Lepor NE J Am Heart Assoc; 2018 Jun; 7(13):. PubMed ID: 29934421 [No Abstract] [Full Text] [Related]